RNAi lines used in this study: erm_RNAi (BDSC #26778), fzr_RNAi (GD#25553), cdc20_RNAi_1 (GD#40500), cdc20_RNAi_2 (GD#44834), ida_RNAi (BDSC#34522); brm_RNAi (GD#37720), β-gal_RNAi (BDSC#50680), and bcd_RNAi (GD#48966).
Neural stem cell drivers included insc-Gal4 (BDSC#8751; 1407-Gal4) or wor-Gal4 (BDSC#56553). Glial driver was repo-Gal4 (BDSC#7415). Type I NSC driver (ase-Gal4; UAS-mCD8-GFP, T. Lee). Type II NSC driver (w; UAS-Dicer2, wor-Gal4, ase-Gal80; UAS-mCD8-GFP) (Bowman et al., 2008 (link)). INP driver (erm-Gal4/CyO) (Pfeiffer et al., 2008 (link)). Other drivers used in this study are: nerfin-1-Gal4, UAS-mCD8-GFP (Louis Y. Cheng), pros-Gal4 (BDSC#80572), and elav-Gal4 (BDSC#458). UAS-Dcr2 (BDSC#24650) or/and UAS-CD8-GFP (BDSC#32186) was used together with various Gal4 drivers or RNAi stocks.
Experiments with mutants were performed at 25°C, and experiments for RNAi-mediated knockdown or overexpression were carried out at 29°C.